Company: INTS
Filing Date: 2025-06-02
Form Type: DEF 14A
Source: 0001567264-25-000050
Chunk: 23

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-06-02
Form: DEF 14A
Chunk 23
---
daq listing requirements, the independent directors regularly have the opportunity to meet without Mr. Bender in attendance. We do not have a lead independent director.

Our board of directors has responsibility for the oversight of our risk management processes and, either as a whole or through its committees, regularly discusses with management our major risk exposures, their potential impact on our business and the steps we take to manage them. The risk oversight process includes receiving regular reports from board committees and members of senior management to enable our board of directors to understand our risk identification, risk management and risk mitigation strategies with respect to areas of potential material risk, including operations, finance, legal, regulatory, cybersecurity, strategic and reputational risk.

Stockholder Communications to our Board of Directors

Any stockholders who wish to address questions regarding our business directly with our board of directors, or any individual director, should direct his or her questions in writing to the Chairman of our board of directors at 1 Enterprise Drive, Suite 430, Shelton, CT 06484-4779. Communications will be distributed to our board of directors, or to any individual director or directors as appropriate, depending on the facts and circumstances outlined in the

<div align='center'>14</div>

communications. Items that are unrelated to the duties and responsibilities of our board of directors may be excluded, such as:

• junk mail and mass mailings;

• resumes and other forms of job inquiries;

• surveys; and

• solicitations or advertisements.

In addition, any material that is unduly hostile, threatening, or illegal in nature may be excluded, in which case it will be made available to any outside director upon request.

#### Executive Officers
The following table sets forth certain information as of June 2, 2025 regarding our executive officers who are not also directors. All of our executive officers are at-will employees.

| Name            |     | Age |     | Position                                    |
| Joseph Talamo   |     |  56 |     | Chief Financial Officer                     |
| John Wesolowski |     |  66 |     | Principal Accounting Officer and Controller |

Joseph Talamo has served as our Chief Financial Officer since December 2023. Prior to joining the Company, from August 2020 until November 2023, Mr. Talamo served as Senior Vice President and Chief Financial Officer of HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse and metastasis. From June 2011 until July 2020, Mr